Alprazolam

證據等級: L5

預測適應症: 10 個

Alprazolam: From Anxiety Disorders to Insomnia

One-Sentence Summary

Alprazolam is a triazolo-benzodiazepine anxiolytic widely used for anxiety disorders and panic disorder. The TxGNN model predicts it may be effective for Insomnia, with 7 clinical trials and 18 publications currently supporting this direction. Evidence is predominantly observational and indirect (L3), with a mechanistically plausible but clinically nuanced case for repurposing.

Quick Overview

Item	Content
Original Indication	Anxiety disorders, panic disorder (general pharmacological class; no Singapore HSA registration on record)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.81%
Evidence Level	L3
Singapore Market Status	✗ Not Registered
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data has not been retrieved from DrugBank for this Evidence Pack. Based on established pharmacology, Alprazolam is a positive allosteric modulator of the GABA-A receptor — the same molecular target underlying all classical benzodiazepine sedative-hypnotics. By amplifying chloride ion influx at GABA-A receptors, it suppresses neuronal excitability throughout the limbic system, reticular activating system, and cortex, producing dose-dependent anxiolytic, sedative, and hypnotic effects.

The mechanistic link to insomnia is direct. GABA-A receptor potentiation shortens sleep-onset latency, reduces the number of nocturnal awakenings, and prolongs NREM (non-REM) sleep — the same neurobiological pathway exploited by approved hypnotic benzodiazepines such as temazepam and triazolam. Anxiety and insomnia are highly comorbid and share overlapping neural substrates (hyperarousal of the hypothalamic-pituitary-adrenal axis and locus coeruleus); the sedating property of alprazolam therefore addresses a core driver of sleep-onset difficulties in anxious patients.

A dedicated prospective real-world cohort (NCT02648776, N = 1,400) and comparative RCTs (PMID 33403184; PMID 39183410) directly document alprazolam use for sleep disturbances, reinforcing the model's prediction. The principal concerns are REM sleep suppression, next-day residual sedation, and a significant risk of physical dependence with sustained use — factors that require careful patient selection and monitoring, particularly in elderly individuals and those with renal or hepatic impairment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02648776	N/A	Unknown	1,400	Prospective cohort study evaluating risk-benefit of commonly prescribed hypnotics (including benzodiazepines) for sleep disorders in Taiwanese elderly; examines drug-use patterns, efficacy, safety, and pharmacogenomic factors directly relevant to insomnia treatment
NCT00266409	Phase 4	Completed	418	Multicenter open-label RCT comparing Niravam™ (alprazolam ODT) + newly initiated SSRI/SNRI vs. SSRI/SNRI alone for generalized anxiety disorder and panic disorder; anxiety-insomnia symptom cluster commonly co-evaluated
NCT01584440	Phase 2	Completed	220	Double-blind, placebo-controlled trial of AVP-923 (dextromethorphan/quinidine) for agitation in Alzheimer's disease; benzodiazepine comparator arm may include sleep-related endpoints
NCT03327506	Phase 4	Unknown	128	Hypnosis vs. alprazolam premedication for perioperative anxiety in laparoscopic gynecological surgery; alprazolam serves as the active comparator, documenting its acute sedative-hypnotic profile
NCT04572750	N/A	Completed	170	Electronic self-management intervention to support benzodiazepine (including alprazolam) cessation in veterans prescribed BZDs mainly for anxiety and sleeping difficulties; provides safety-focused real-world data on long-term use patterns
NCT01893632	Phase 2	Terminated	2	Gabapentin for benzodiazepine dependence; terminated early due to extremely low enrollment (N = 2), provides no usable efficacy data
NCT01146600	Phase 2	Completed	26	Clarithromycin for hypersomnia; neither the study drug nor the indication is directly relevant to alprazolam in insomnia

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33403184	2020	Comparative RCT	Cureus	Alprazolam vs. melatonin for sleep disorders in end-stage renal disease patients on hemodialysis; directly compares alprazolam's hypnotic efficacy and safety in a medically complex population
39183410	2024	RCT (Integrative)	Medicine	Retrospective study (N = 116) of coronary heart disease patients with insomnia; alprazolam was the standard-of-care control arm, confirming its clinical use for comorbid insomnia and documenting neurotransmitter outcomes
35041261	2022	RCT	Brain and Behavior	Eszopiclone vs. alprazolam for sleep quality and cognitive function in elderly Alzheimer's patients with sleep disorder; head-to-head comparison providing sleep efficacy benchmarking data
36692463	2023	Meta-analysis	Acta Pharmaceutica (Zagreb)	Systematic review of RCTs and cohort studies on tranquilizers (including benzodiazepines) in elderly patients with chronic non-communicable diseases; evaluates dose, efficacy outcomes, and adverse effects
37984023	2024	Utilization/Predictive Model	Value in Health Regional Issues	10-year predictive model of benzodiazepine prescribing trends in Croatia; documents broad real-world use for insomnia, anxiety, and mood disorders, and quantifies long-term safety risks including dependence and cognitive decline
38363887	2024	Cross-sectional	Medicine	Insomnia prevalence and risk factors among COVID-19 survivors; contextualises the unmet need for pharmacological insomnia management in post-infectious populations
37801512	2023	Mechanistic Study	Aging	Repeated alprazolam administration in mice causes mitochondrial dysfunction and hippocampal memory consolidation impairment; quantifies neurological risk signal from chronic use relevant to long-term insomnia therapy
35493764	2022	Cohort Study	JHEP Reports	Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis; important safety signal for benzodiazepine/hypnotic class in hepatic impairment, applicable to alprazolam safety profiling
25532388	2014	Real-World Study	China Journal of Chinese Materia Medica	Real-world analysis of concurrent diseases and medication use in 1,067 insomnia patients; documents benzodiazepine prescribing patterns in clinical practice
23330992	2013	PK Review	Expert Opinion on Drug Metabolism & Toxicology	Pharmacokinetics of anxiolytics including alprazolam; provides dosing, half-life, and bioavailability context relevant to hypnotic dosing strategy design

Singapore Market Information

Alprazolam (DrugBank ID: DB00404) currently has no active product registrations with the Health Sciences Authority (HSA) of Singapore. There are no approved products to list.

Alprazolam is classified as a controlled substance (Schedule IV under the US Controlled Substances Act and analogously regulated in many jurisdictions). Any market entry strategy for Singapore would need to account for the Misuse of Drugs Act (MDA) scheduling requirements and relevant HSA controlled drug import/dispensing regulations.

Safety Considerations

Safety data (key warnings, contraindications, and drug-drug interactions) were not available in this Evidence Pack.

Please refer to the approved package insert for full safety information. As a benzodiazepine, standard class-level precautions are expected to apply, including risks of central nervous system depression, respiratory depression (particularly when combined with opioids or alcohol), physical dependence, withdrawal syndrome upon abrupt discontinuation, anterograde amnesia, and impaired psychomotor performance. The mechanistic study (PMID 37801512) additionally flags mitochondrial dysfunction and memory impairment with repeated dosing.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alprazolam's GABA-A receptor mechanism directly supports hypnotic activity, multiple real-world studies and comparative RCTs confirm its use for sleep disturbances, and the TxGNN prediction score (99.81%) is among the highest in this candidate set. However, the evidence base is classified as L3 (observational/indirect), the drug is not currently registered in Singapore, and critical safety data are absent — warranting a structured, conditional approach before advancing.

To proceed, the following is needed:

Retrieval of formal MOA and safety data from DrugBank (DG002) to complete the mechanistic rationale
Download and parsing of the approved package insert (TFDA or comparable authority) for key warnings and contraindications (DG001 — Blocking severity)
Regulatory pathway assessment for Singapore HSA registration, including controlled substance scheduling classification under the Misuse of Drugs Act
A dedicated Phase 2/3 RCT specifically for alprazolam in primary insomnia (current trial evidence is largely indirect or comparator-arm based)
Long-term dependence risk management plan (gradual dose tapering protocols, maximum treatment duration guidelines)
Special population safety data: elderly patients (fall risk, cognitive effects), renal impairment (ESRD), and hepatic impairment (cirrhosis)
Head-to-head comparison data against current first-line non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone, melatonin receptor agonists) to define a competitive clinical positioning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.